The Clinical Role of Molecular Imaging: Positron Emission Tomography/Computed Tomography and (90)Yttrium-DOTATOC in the Management of Medullary Thyroid Cancer
Restricted accessLetterFirst published online February, 2010
The Clinical Role of Molecular Imaging: Positron Emission Tomography/Computed Tomography and (90)Yttrium-DOTATOC in the Management of Medullary Thyroid Cancer
American Thyroid Association Guidelines Task Force. KloosRT, EngC, EvansDB, FrancisGL, GagelRF, GharibH, MoleyJF, PaciniF, RingelMD, SchlumbergerM, WellsSAJr.2009. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19:565–612.
2.
RufiniV, TregliaG, PerottiG, LeccisottiL, CalcagniML, RubelloD. 2008. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol, 33:67–73.
3.
KauhanenS, SeppanenM, OvaskaJ, MinnH, BergmanJ, KorsoffP, SalmelaP, SaltevoJ, SaneT, ValimakiM, NuutilaP. 2009. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer, 16:255–265.
4.
KoopmansKP, de GrootJW, PlukkerJT, de VriesEG, KemaIP, SluiterWJ, JagerPL, LinksTP. 2008. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med, 49:524–531.
5.
OudouxA, SalaunPY, BournaudC, CampionL, AnsquerC, RousseauC, BardetS, Borson-ChazotF, VuillezJP, MuratA, MirallieE, BarbetJ, GoldenbergDM, ChatalJF, Kraeber-BodereF. 2007. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab, 92:4590–4597.
6.
CzepczynskiR, KosowiczJ, MikołajczakR, ZiemnickaK, GryczynskaM, SowinskiJ. 2006. New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma. Pol Arch Med Wewn, 116:853–860.
7.
ItenF, MullerB, SchindlerC, RochlitzC, OertliD, MackeHR, Muller-BrandJ, WalterMA. 2007. Response to [90Yttrium-DOTA]-TOC treatment is associated with longterm survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res, 13:6696–6702.
